JP2004537305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537305A5 JP2004537305A5 JP2003511773A JP2003511773A JP2004537305A5 JP 2004537305 A5 JP2004537305 A5 JP 2004537305A5 JP 2003511773 A JP2003511773 A JP 2003511773A JP 2003511773 A JP2003511773 A JP 2003511773A JP 2004537305 A5 JP2004537305 A5 JP 2004537305A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- cells
- vsv
- cell
- gene regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cells Anatomy 0.000 description 19
- 230000001105 regulatory Effects 0.000 description 12
- 241000711975 Vesicular stomatitis virus Species 0.000 description 9
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 229920002676 Complementary DNA Polymers 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000004185 Liver Anatomy 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000007698 EC 1.1.1.1 Human genes 0.000 description 2
- 108010021809 EC 1.1.1.1 Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 101700086558 CELA1 Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 102100019126 HBB Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit beta Proteins 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229920001204 Intergenic region Polymers 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 102100000921 MYL2 Human genes 0.000 description 1
- 238000006968 MacDonald synthesis reaction Methods 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 102000015528 Myelin Basic Protein Human genes 0.000 description 1
- 108010025255 Myelin Basic Protein Proteins 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 210000004248 Oligodendroglia Anatomy 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 229940024142 alpha 1-Antitrypsin Drugs 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 108010003152 bacteriophage T7 RNA polymerase Proteins 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 229920000407 conserved sequence Polymers 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 108060003523 dnaK Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
Images
Description
宿主細胞の感染の後に、組換えVSVは宿主細胞タンパク質合成をシャットダウンしそしてそれ自体の5つの遺伝子産物だけではなくそのゲノム中にコードされた異種タンパク質も発現する。VSV組換え体由来の異種核酸の首尾よい発現は、VSV遺伝子接合部の各々において見出される最小限の保存された配列を伴った全長cDNAへの異種核酸配列の添加のみを必要とする。この配列は、ポリアデニル化/転写停止シグナル(3’AUACU7)(配列番号1)、その後の遺伝子間ジヌクレオチド(GAまたはCA)およびVSV mRNAの5’に対して相補的な転写開始配列(3’UUGUCNNUAG)(配列番号2)からなる。Ballら1999,J.Virol.73:4705−4712;Lawsonら1995,P.N.A.S.USA 92:4477−4481;Whelanら1995,P.N.A.S.USA 92:8388−8392。さらに、(好ましくは、固有の)制限部位(これは、例えば、ポリリンカー中にある)が、VSV cDNA(例えば、遺伝子間領域)に導入され、異種核酸(例えば、インターロイキンまたはインターフェロンをコードする核酸)の挿入を促進する。他の実施例において、このVSV cDNAは、それに作動可能に連結したプロモーターを有するように構築されている。このプロモーターは、その組換えVSVベクターを産生することが所望される動物細胞または昆虫細胞におけるそのcDNAの転写を開始することができるはずである。使用され得るプロモーターとしては、以下が挙げられ得るがこれらに限定されない:SV40初期プロモーター領域(BernoistおよびChambon,1981,Nature 290:304−310)、Rous sarcomaウイルスの3’長末端反復に含まれるプロモーター(Yamamoto,et al.,1980,Cell 22:787−797)、ヘルペスチミジンキナーゼプロモーター(Wagnerら,1981,Proc.Natl.Acad.Sci.U.S.A.78:1441−1445)、メタロチオネイン遺伝子の調節配列(Brinsterら,1982,Nature 296:39−42);熱ショックプロモーター(例えば、ショウジョウバエS2細胞での使用のためのhsp70);ADC(アルコールデヒドロゲナーゼ)プロモーター、PGK(ホスホグリセロールキナーゼ)プロモーター、アルカリホスファターゼプロモーター、ならびに以下の動物転写制御領域(これらは、組織特異性を提示しかつトランスジェニック動物中で使用されてきている):膵臓腺房細胞おいて活性であるエラスターゼI遺伝子制御領域(Swiftら,1984,Cell 38:639−646;Ornitzら,1986,Cold Spring Harbor Symp.Quant.Biol.50:399−409;MacDonald,1987,Hepatology 7:425−515);膵臓β細胞において活性であるインスリン遺伝子制御領域(Hanahan,1985,Nature 315:115−122)、リンパ細胞中で活性である免疫グロブリン遺伝子制御領域(Grosschedlら,1984,Cell 38:647−658;Adamesら,1985,Nature 318:533−538;Alexanderら,1987,Mol.Cell.Biol.7:1436−1444)、精巣細胞、***細胞、リンパ系細胞、および肥満細胞において活性であるマウス乳腺癌ウイルス制御領域(Lederら,1986,Cell 45:485−495)、肝臓において活性であるアルブミン遺伝子制御領域(Pinkertら,1987,GenesおよびDevel.1:268−276)、肝臓で活性であるα−フェトプロテイン遺伝子制御領域(Krumlaufら,1985,Mol.Cell.Biol.5:1639−1648;Hammerら,1987,Science 235:53−58);肝臓で活性であるα1−抗トリプシン遺伝子制御領域(Kelseyら,1987,Genes and Devel.1:161−171)、骨髄細胞で活性であるβ−グロビン遺伝子制御領域(Mogramら,1985,Nature 315:338−340;Kolliasら,1986,Cell 46:89−94);脳の中の希突起神経膠細胞において活性なミエリンベーシックプロテイン遺伝子制御領域(Readheadら,1987,Cell 48:703−712);ならびに骨格筋で活性であるミオシン軽鎖−2遺伝子制御領域(Sani,1985,Nature 314:283−286)。好ましくは、このプロモーターは、RNAポリメラーゼプロモーター、好ましくは、バクテリオファージまたはウイルスまたは昆虫のRNAポリメラーゼプロモーターであり、これらのプロモーターとしては、以下が挙げられるがこれらに限定されない:T7 RNAポリメラーゼに対するプロモーター、SP6 RNAポリメラーゼに対するプロモーター、およびT3 RNAポリメラーゼに対するプロモーター。RNAポリメラーゼプロモーターが使用される場合(ここで、このRNAポリメラーゼは、宿主細胞によって内因的に産生されておらず、この宿主細胞において、その組換えVSVが産生されることが所望される)、RNAポリメラーゼの組換え供給源は、宿主細胞中において提供されなければならない。このようなRNAポリメラーゼは、当該分野で公知である。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30412501P | 2001-07-11 | 2001-07-11 | |
PCT/US2002/022146 WO2003005964A2 (en) | 2001-07-11 | 2002-07-11 | Recombinant vsv for the treatment of tumor cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004537305A JP2004537305A (ja) | 2004-12-16 |
JP2004537305A5 true JP2004537305A5 (ja) | 2006-01-05 |
Family
ID=23175155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003511773A Pending JP2004537305A (ja) | 2001-07-11 | 2002-07-11 | 腫瘍細胞の処置のための組換えvsv |
Country Status (5)
Country | Link |
---|---|
US (4) | US20030044386A1 (ja) |
EP (1) | EP1411880B1 (ja) |
JP (1) | JP2004537305A (ja) |
CA (1) | CA2452517A1 (ja) |
WO (1) | WO2003005964A2 (ja) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2439014T3 (es) | 1998-02-20 | 2014-01-21 | The University Of Miami | Complejo de péptido antigénico-proteína de choque térmico modificada |
WO2004066947A2 (en) * | 2003-01-28 | 2004-08-12 | Shanghai Sunway Biotech Co., Ltd. | Hyperthermia oncolysis co-therapy |
CN1764474B (zh) * | 2003-03-26 | 2011-02-02 | 惠氏公司 | 免疫原性组合物及方法 |
US8012747B2 (en) * | 2004-06-01 | 2011-09-06 | San Diego State University Foundation | Expression system |
CN1769433B (zh) * | 2004-11-04 | 2011-03-16 | 张庆勇 | 重组水疱性口炎病毒及其应用 |
NZ554429A (en) | 2004-11-12 | 2010-08-27 | Bayer Schering Pharma Ag | Recombinant newcastle disease virus comprising a transgene encoding a antibody or antibody like fragment or derivative thereof for use in cancer treatments |
US20100086522A1 (en) * | 2006-07-18 | 2010-04-08 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
EP2085092A1 (en) | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
CN102014937A (zh) | 2008-03-03 | 2011-04-13 | 迈阿密大学 | 基于异基因癌细胞的免疫治疗 |
EP2274001A4 (en) * | 2008-03-20 | 2012-08-01 | Univ Miami | GP96 THERMAL IMPACT PROTEIN VACCINATION AND METHODS OF USE |
WO2009135614A2 (en) * | 2008-05-09 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | Use of a virus regimen for the treatment of diseases |
US10265357B2 (en) | 2008-10-08 | 2019-04-23 | Viratherapeutics Gmbh | Compositions, methods and uses for treating solid tumors using LCMV-GP-VSV pseudotype vectors |
DE102008050860A1 (de) * | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
US20100143889A1 (en) * | 2008-12-02 | 2010-06-10 | Mayo Foundation For Medical Education And Research | Rhabdoviridae virus preparations |
WO2010147971A2 (en) * | 2009-06-15 | 2010-12-23 | New York University | Il23 modified viral vector for recombinant vaccines and tumor treatment |
US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
EP2611920B1 (en) * | 2010-09-02 | 2015-05-13 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
EP2764119A2 (en) | 2011-10-05 | 2014-08-13 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
CN103301447B (zh) * | 2013-06-25 | 2014-12-31 | 哈尔滨医科大学 | DNA-PKcs在制备改变肿瘤细胞对MTX耐药性的药物中的应用 |
WO2015077714A1 (en) * | 2013-11-22 | 2015-05-28 | Yale University | Chimeric vsv virus compositions and methods of use thereof for treatment of cancer |
WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
CN108064282A (zh) | 2014-10-14 | 2018-05-22 | 哈洛齐梅公司 | 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法 |
BR112017016681A2 (pt) | 2015-02-06 | 2018-04-10 | Heat Biologics Inc | vetor de coexpressão de vacina e moléculas coestimulatórias |
WO2016185414A1 (en) * | 2015-05-19 | 2016-11-24 | British Columbia Cancer Agency Branch | Recombinant oncolytic viruses and uses thereof |
KR102536850B1 (ko) | 2016-04-15 | 2023-05-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
CA3032120A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
WO2018071405A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
US20200040059A1 (en) | 2016-10-20 | 2020-02-06 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
US11920156B2 (en) | 2017-02-09 | 2024-03-05 | Indapta Therapeutics, Inc. | Engineered natural killer (NK) cells and compositions and methods thereof |
FI3596116T3 (fi) | 2017-03-16 | 2023-11-09 | Alpine Immune Sciences Inc | Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä |
CN110662758A (zh) | 2017-03-16 | 2020-01-07 | 高山免疫科学股份有限公司 | Cd80变体免疫调节蛋白及其用途 |
KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
WO2018187260A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
CN111712515A (zh) | 2017-10-18 | 2020-09-25 | 高山免疫科学股份有限公司 | 变体icos配体免疫调节蛋白及相关组合物和方法 |
CA3097850A1 (en) * | 2018-03-26 | 2019-10-03 | University Of Miami | Recombinant viral vector and uses thereof |
US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
KR102662837B1 (ko) | 2018-06-04 | 2024-05-03 | 카리디 바이오테라퓨틱스, 인크. | 바이러스 치료법의 강화를 위한 세포-기반 비히클 |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
CA3177862A1 (en) | 2018-11-06 | 2020-05-14 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
KR20210123289A (ko) | 2018-11-21 | 2021-10-13 | 인답타 세라뷰틱스 인코포레이티드 | 자연 살해 세포 서브세트의 증식을 위한 방법 및 관련 조성물 및 방법 |
WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
CA3176660A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
JP2023523429A (ja) | 2020-04-22 | 2023-06-05 | インダプタ セラピューティクス インコーポレイテッド | ナチュラルキラー(nk)細胞組成物およびそれを生成させるための方法 |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552304A (en) * | 1985-11-19 | 1996-09-03 | Schering Corporation | CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4) |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
PT702085E (pt) * | 1994-07-18 | 2004-04-30 | Karl Klaus Conzelmann | Virus de arn de cadeia negativa nao segmentada infeccioso recombinante |
US5789229A (en) * | 1994-09-30 | 1998-08-04 | Uab Research Foundation | Stranded RNA virus particles |
US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US7081243B1 (en) * | 1997-07-11 | 2006-07-25 | Yale University | Rhabdoviruses with reengineered coats |
NZ505312A (en) * | 1997-12-22 | 2003-01-31 | Univ Tennesse Res Corp | Recombinant Vesicular Stomatitis virus comprising a heterologous F protein (Paramyxovirus strain SV5) and CD4 antireceptor protein |
US6329175B1 (en) * | 1998-09-18 | 2001-12-11 | Zymogenetics, Inc. | Interferon-ε |
ES2320239T3 (es) * | 1999-09-17 | 2009-05-20 | Wellstat Biologics Corporation | Virus oncolitico. |
WO2002000233A2 (en) * | 2000-06-26 | 2002-01-03 | Wellstat Biologics Corporation | Purging of cells using viruses |
AU2003268505A1 (en) * | 2002-09-09 | 2004-03-29 | University Of Tennessee Research Foundation | Recombinatant mutants of rhabdovirus and methods of use thereof |
-
2002
- 2002-07-11 CA CA002452517A patent/CA2452517A1/en not_active Abandoned
- 2002-07-11 WO PCT/US2002/022146 patent/WO2003005964A2/en active Application Filing
- 2002-07-11 EP EP02749985.4A patent/EP1411880B1/en not_active Expired - Lifetime
- 2002-07-11 US US10/194,594 patent/US20030044386A1/en not_active Abandoned
- 2002-07-11 JP JP2003511773A patent/JP2004537305A/ja active Pending
-
2008
- 2008-07-18 US US12/175,898 patent/US20100113567A1/en not_active Abandoned
-
2012
- 2012-12-21 US US13/724,393 patent/US20130210135A1/en not_active Abandoned
-
2015
- 2015-07-29 US US14/812,454 patent/US20160022748A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004537305A5 (ja) | ||
WO2000049150A1 (en) | Chimeric gene constructs for generation of fluorescent transgenic ornamental fish | |
Sivasubbu et al. | Gene-breaking transposon mutagenesis reveals an essential role for histone H2afza in zebrafish larval development | |
JP2007520236A (ja) | 抗凍結タンパク質により高められた核酸増幅 | |
WO1998015627A1 (en) | Production of recombinant peptide by transgenic fish | |
JP4701336B2 (ja) | ヒト・コラーゲンを産生する形質転換カイコ | |
US7355095B2 (en) | Method for producing heart-specific fluorescence of non-human eukaryotic animals | |
Wang et al. | Mitochondrial genome of the Shorthead catfish (Pelteobagrus eupogon) | |
CN116262926B (zh) | 一种非加帽线性rna重组核酸分子及其应用 | |
CN1196784C (zh) | 人内皮特异受体基因的启动子及其用途 | |
CN1354183A (zh) | 肿瘤凋亡诱导配体基因、基因表达蛋白及其制备方法 | |
CN1388248A (zh) | 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法 | |
CN1365392A (zh) | 果蝇重组相关蛋白质及其使用方法 | |
TWI291963B (en) | Expression of zebrafish bone morphogenetic protein 4 | |
JP4544834B2 (ja) | 外来遺伝子発現を促進するポリヌクレオチド | |
JP4793842B2 (ja) | ランダムrnaプライマーを用いたdnaの増幅方法 | |
Le Jossic et al. | Striking evolutionary conservation of a cis-element related to nuclear receptor target sites and present in TR2 orphan receptor genes | |
CN113416743B (zh) | 核酸分子、PCR引物对及用于检测禽毛滴虫rpoB基因的试剂盒 | |
US20040250308A1 (en) | Method for direct nucleic acid uptake | |
Parenrengi et al. | Analysis of promoter activity on tiger shrimp Penaeus monodon using EGFP (enhanced green fluorescent protein) as a marker gene | |
CN1283794C (zh) | 节旋藻藻蓝蛋白基因的启动子及其制备方法 | |
KR20240086779A (ko) | 다중 단백질의 발현을 위한 신규 핵산 구조체 | |
RU2006115404A (ru) | Способ контроля качества вакцинации цыплят против болезни марека | |
CN117904120A (zh) | Fgfr3基因突变致软骨发育低下小鼠模型构建方法及其应用 | |
JP2010124782A (ja) | 線虫を用いたタンパク質の生産方法 |